Most Recent
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
EnergyAustralia has lost its appeal of a finding that it's on the hook for portable long service leave for maintenance workers at its Yallourn power station because its significant maintenance activities mean it's 'in the construction industry', a ruling that could affect energy, rail and telecommunications firms.
Construction PRO
EnergyAustralia has lost its appeal of a finding that it's on the hook for portable long service leave for maintenance workers at its Yallourn power station because its significant maintenance activities mean it's 'in the construction industry', a ruling that could affect energy, rail and telecommunications firms.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.
A former director of marketing companies linked to the failed Shield and First Guardian funds says ASIC's 14-month investigation has left him facing a travel ban and freezing orders but no substantive allegations.
Construction PRO
A Western Sydney council has lost its bid to keep expert evidence in an arbitration with a builder under wraps in its $7 million case alleging a Sydney architect is liable for defects in a tennis court complex.
Construction PRO
Builder Watpac has lost its bid for a separate hearing on whether a guarantee provided to the developer of Sydney's One Central Park is time-barred, with a judge saying the question should wait until $180 million in defects claims are determined.
Bentleys Wealth is suing a former director and his companies alleging he poached clients after leaving the firm, in breach of his employment agreement and various duties.
AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege.